Autopsy report · NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Cause of deathDrug or device supply
“NCI stopped supplying fenretinide in November of 2012.”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 7 years 9 months before it stopped.
- 32 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma
- Interventions
- fenretinide; rituximab
- Participants
- 32
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.